SCHEMBL30651

SCHEMBL30651

C=CCC(N)(CC=C)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
FGFR4 P22455 1/20 0.36
ODC1 P11926 1/20 0.35
ARG2 P78540 5/20 0.32
ARG1 P05089 4/20 0.32
LMNA P02545 1/20 0.32
GRIK1 P39086 2/20 0.30
GRIK2 Q13002 2/20 0.30
ABCC4 O15439 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30787966 0.88 ARG2 (0.41) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL1416684 0.86 ALDH1A1 (0.37) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL1416683 0.86 ALDH1A1 (0.37) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL5904292 0.86 ALDH1A1 (0.50) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL3854199 0.86 ALDH1A1 (0.37) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL11087825 0.86 ODC1 (0.48) ALDH1A1TSHRHTTMEN1CYP1A2
Hydrochloric Acid SCHEMBL2302947 0.86 ARG2 (0.40) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL3852730 0.84 ALDH1A1 (0.36) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL29962101 0.84 ALDH1A1 (0.36) ALDH1A1TSHRHTTMEN1CYP1A2
SCHEMBL3852726 0.84 ALDH1A1 (0.36) ALDH1A1TSHRHTTMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023389-B2 Compositions that target tumor-associated macrophages and methods of use therefor Sanford Burnham Prebys Medical Discovery Institute (US) 2024-07-02 US disclosed
US-20240150397-A1 TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute 2024-05-09 US disclosed
US-20240131201-A1 COMPOSITIONS THAT TARGET TUMOR-ASSOCIATED MACROPHAGES AND METHODS OF USE THEREFOR Sanford Burnham Prebys Medical Discovery Institute 2024-04-25 US disclosed
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-04-11 US disclosed
US-20230414704-A1 Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making Same SANFORD-BURNHAM MEDICAL DISCOVERY INSTITUTE 2023-12-28 US disclosed
EP-3912986-B1 CRP CAPTURE/DETECTION OF BACTERIA HARVARD COLLEGE (US) 2023-12-13 EP disclosed
US-11807677-B2 Microbe-binding molecules and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-11-07 US disclosed
US-11795212-B2 Engineered microbe-targeting molecules and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-10-24 US disclosed
US-11718651-B2 CRP capture/detection of gram positive bacteria PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-08-08 US disclosed
US-11642391-B2 Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same VASCULAR BIOSCIENCES (US) 2023-05-09 US disclosed
US-20030232762-A1 Breast homing peptides and methods of identifying same using aminopeptidase P BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-12-18 US disclosed
US-20030143651-A1 Fret protease assays for clostridial toxins ALLERGAN, INC. 2003-07-31 US disclosed
US-20030143650-A1 Fret protease assays for botulinum serotype A/E toxins ALLERGAN, INC. 2003-07-31 US disclosed
US-20030077664-A1 Methods of screening for compounds that modulate hormone receptor activity ADVANCED MEDICAL OPTICS, INC. 2003-04-24 US disclosed
WO-2003020948-A2 FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS ALLERGAN, INC. (US) 2003-03-13 WO disclosed
US-RE35754-E FOR TREATING BACTERIAL INFECTIONS HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-24 US disclosed
US-5710146-A ANTIBIOTICS FOR BACTERICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1998-01-20 US disclosed
US-5089490-A Cephem derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1992-02-18 US disclosed
US-4758556-A Cephem derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1988-07-19 US disclosed
US-4278793-A ANTIBIOTICS, BACTERICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1981-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 ALDH1A1 2700/4885TSHR 583/4885HTT 3937/4885
US-20030232762-A1 Breast homing peptides and methods of identifying same using aminopeptidase P DNPEP, ANPEP, DPEP1 ALDH1A1 1359/4885TSHR 3484/4885HTT 4469/4885
US-20030143650-A1 Fret protease assays for botulinum serotype A/E toxins BTD, ADAM33, ADAM17 ALDH1A1 3750/4885TSHR 1765/4885HTT 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.